参松养心胶囊对急性冠脉综合征合并慢快综合征的临床疗效观察

Clinical Effect of Shensong Yangxin Capsule(参松养心胶囊)on Acute Coronary Syndrome Combined with Fast And Slow Syndrome

目的观察参松养心胶囊对急性冠脉综合征(acute coronary syndrome,ACS)合并慢快综合征患者的临床疗效。方法选择辽宁中医药大学附属医院心内科2020年9月—2021年7月收治共122例ACS合并慢快综合征的患者,将其分为治疗组61例,对照组61例。治疗组在西医传统药物治疗基础上,联合应用参松养心胶囊,对照组采用西医传统药物进行相应的对症处理。对两组治疗前后的疗效进行对比分析。包括主观的临床症状、24 h动态心电图平均心率、低密度脂蛋白(LDL-C)、胆固醇(TC)的改善情况及不良反应(头晕、心悸、腹胀腹泻、恶心呕吐、失眠)发生率及再住院率的影响。结果从患者主观的临床症状来看,治疗组临床总有效率显著高于对照组(P<0.05),平均24 h动态心电图(ECG)心率明显高于对照组(P<0.05),血清LDL-C和TC的降低幅度比对照组大(P<0.05),并且两组的不良反应和再次入院率都比对照组要低(P<0.05)。结论参松养心胶囊治疗ACS合并慢快综合征的临床症状及相关血清学指标改善更为明显,且不良反应(心慌、气短心动过速、恶心呕吐、头痛)发生率及再住院率更低。总体看来,参松养心胶囊通过联合常规西药对症治疗ACS合并慢快综合征患者临床疗效较西药对症治疗具有明显优势其安全性也值得肯定。

Objective To observe the clinical efficacy of Shensong Yangxin capsule(参松养心胶囊)in patients with Acute Coronary Syndrome(ACS)combined with slow-fast syndrome.Methods A total of 122 patients with ACS and slow-fast syndrome admitted from September 2020 to July 2021 were selected and divided into treatment and control group,61 in each group.The treatment group refers to the combination of Shensong Yangxin capsule based on the symptomatic treatment of traditional western medicine,and the control group uses traditional western medicine for the corresponding symptomatic treatment.The clinical symptoms of the two groups and the efficacy before and after treatment were compared.Including the patient's subjective clinical symptoms,the mean heart rate of the 24-hour holter electrocardiogram,the improvement of serum low-density lipoprotein(LDL-C),cholesterol(TC)and the effect of adverse reactions(dizziness,palpitations,abdominal distension,diarrhea,nausea,vomiting,insomnia)and the impact of rehospitalization rate.Results Regarding the subjective improvement of patient clinical symptoms,the total clinical response rate was significantly higher in the control group,and the mean heart rate of the 24-hour Holter ECG was significantly higher than in the control group.The serum reductions in LDL-C and TC were greater than in the controls and were significantly different,and the side effects and readmission rates were lower than in the control group.Conclusion The clinical symptoms and related serological indexes of ACS combined with slow-fast syndrome were more significantly improved,and the incidence of adverse reactions(palpitation,shortness of breath tachycardia,nausea and vomiting,headache)and the rehospitalization rate were lower.In general,the clinical efficacy of ACS combined with slow-fast syndrome has obvious advantages compared with western medicine,and its safety is also worthy.